检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:常学辉[1] 张良芝[2] 黎民[1] CHANG Xue-hui;ZHANG Liang-zhi;LI Min(The Second Clinical Medical College of Henan University of Chinese Medicine,Zhengzhou 450002,China;Basic Medical College of Henan University of Chinese Medicine,Zhengzhou 450008,China)
机构地区:[1]河南中医药大学第二临床医学院,河南郑州450002 [2]河南中医药大学基础医学院,河南郑州450008
出 处:《中成药》2018年第8期1681-1686,共6页Chinese Traditional Patent Medicine
基 金:河南省高等学校重点科研项目(16A360019)
摘 要:目的观察龟羚帕安丸对帕金森病大鼠神经干细胞移植后中脑黑质TH、GDNF、Ptx3表达的影响。方法 6-羟基多巴注射法建立帕金森病模型后,60只造模大鼠随机分为空白对照组,美多芭组,龟羚帕安丸高、中、低剂量组,神经干细胞移植组,各组灌胃给药28 d。然后,免疫组化法检测大鼠中脑黑质TH、GDNF、Ptx3蛋白表达,原位杂交法检测TH mRNA表达。结果与神经干细胞移植组比较,美多芭组、龟羚帕安丸组TH、GDNF、Ptx3蛋白及TH mRNA表达均显著增加(P<0.01)。结论龟羚帕安丸可增加帕金森病大鼠中脑黑质TH、GDNF、Ptx3蛋白表达,可能是其治疗帕金森病的作用机制之一。AIM To observe the effects of post neural stem cell transplantation use of Guiling Pa'an Pills on expressions of TH,GDNF and Ptx3 in midbrain substantia nigra of Parkinson' s disease rats. METHODS The sixty 6-hydroxydopamine injection-induced rat models of Parkinson' s disease randomly divided into blank control group,Madopar group,high,medium,and low dose Guiling Pa'an Pills groups,and neural stem cell transplantation group were given 28 days intragastric administration,respectively,after which their expressions of TH,GDNF,Ptx3 proteins in midbrain substantia nigra were detected by immunohistochemistry,and their expression of TH mRNA was analyzed by in situ hybridization. RESULTS Compared with the neural stem cell transplantation group,Madopar group and Guiling Pa 'an Pills groups shared more significantly increased expressions of TH,GDNF,Ptx3 proteins and TH mRNA( P〈0. 01). CONCLUSION Guiling Pa'an Pills can treat Parkinson' s disease due to its action mechanism in increasing the expressions of TH,GDNF,Ptx3 proteins in midbrain substantia nigra of Parkinson's disease rats.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15